# Southwest EDRN Clinical Validation Center for Head and Neck Cancer

> **NIH NIH U01** · ARIZONA STATE UNIVERSITY-TEMPE CAMPUS · 2024 · $963,127

## Abstract

Project Summary/Abstract
The goal of the EDRN Southwest Clinical Validation Center for Head and Neck Cancer is to improve oropharyngeal cancer
screening through the rigorous validation of salivary biomarkers. The scientific approach of our Center is based on several
fundamental principles. First, that human papillomaviral (HPV) infection and persistence induces carcinogenesis in the
oropharynx over decades, generating well-documented circulating and salivary viral nucleic acid and serologic biomarkers.
These biomarkers have not yet been tested in rigorous, prospective studies with centralized CLIA/CAP biomarker validation.
Second, the low incidence requires that effective screening paradigms for oropharyngeal cancers (OPC) use novel systems
for large-scale prospective studies using self-collection sampling, digital enrollment, and distributive systems to enable
enrollment in underserved communities. Third, that the clinical management of positive biomarkers be rigorously addressed.
Our proposal builds on our extensive experiences with cancer biomarker development, verification, validation, innovative
clinical study management, and expertise in HPV oropharyngeal cancer screening. Our previous results on HPV serologic
biomarkers have been confirmed in blinded phase 2 multicenter validation studies. Our results have shown that multiplexed
panels of IgG antibodies for HPV16 are required for adequate predictive value. Our Meso Scale Diagnostics, LLC. (MSD®)
team has fielded over 3,000 instruments worldwide, and over 700 commercially available biomarker assay kits. Their
expertise at serologic assay development led to one of their V-PLEX® serology panels being selected by Operation Warp
Speed as the basis of its standard binding assays for immunogenicity assessments in all funded Phase III clinical trials of
COVID vaccines. We will use the MSD MULTI-ARRAY® platform to migrate the HPV serologic markers for target clinical
applications in saliva. This represents an ongoing collaboration with experts in large-scale self-collection salivary biomarker
screening at Arizona State University, experts on head and neck cancer screening at Baylor University Medical Center, and
AT Still University (ATSU) School of Dentistry and Oral Health. We will generate high-quality well-characterized samples to
validate circulating and salivary biomarkers to enhance oropharyngeal cancer screening. Adhering to the principles of
PRoBE design, we will perform Phase 2 validation of HPV serology and nucleic acid testing with cancer patient and control
sera and saliva, followed by developing and testing the methodology needed to conduct a prospective Phase 4 salivary
screening study. We will provide a resource for expertise and clinical repository for the rigorous validation of salivary and
circulating biomarkers for cancer screening.

## Key facts

- **NIH application ID:** 10893364
- **Project number:** 5U01CA281660-02
- **Recipient organization:** ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
- **Principal Investigator:** Karen Sue Anderson
- **Activity code:** U01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $963,127
- **Award type:** 5
- **Project period:** 2023-08-01 → 2028-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10893364

## Citation

> US National Institutes of Health, RePORTER application 10893364, Southwest EDRN Clinical Validation Center for Head and Neck Cancer (5U01CA281660-02). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10893364. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*